The p-amyloid precursor protein @APP) is a widely expressed membrane-spanning glycoprotein, isoforms of which arise by alternative splicing of a pre-mRNA transcribed from a gene on human chromosome 21. The initial cloning (Kang et al., 1987) and characterization of /3APP followed the identification of an -40 residue fragment, the amyloid @-protein (APP), as the subunit of the amyloid fibrils that are progressively deposited in meningocerebral blood vessels (Glenner and Wong, 1984) and cerebral plaques (Masters et al., 1985b , Selkoe et al., 1986 ) in Alzheimer's disease and trisomy 2 1. BAPP mRNAs and proteins have been detected in many mammalian tissues and cell lines (see, e.g., Goldgaber et al., 1987; Robakis et al., 1987; Tanzi et al., 1987; Neve et al., 1988; Selkoe et al., 1988; Tanaka et al., 1989; Weidemann et al., 1989) and the molecule shows a high degree of evolutionary conservation (Yamada et al., 1987; Shivers et al., 1988; Podlisny et al., 199 1) . In addition to the initially cloned 695 residue isoform (PAPP,,,), three alternative transcripts (/3APP563, PAPP,,, , and PAPP,,,) have been identified that contain an inserted exon having -50% homology with the Kunitz family of serine protease inhibitors (Kitaguchi et al., 1988; Ponte et al., 1988; Tanzi et al., 1988; De Sauvage and Octave, 1989) . Several putative functions have been ascribed to pAPP or its proteolytic fragments based on in vitro studies, including inhibition of extracellular serine proteases (Van Nostrand and Cunningham, 1987; Kitaguchi et al., 1988; Sinha et al., 1990) . Indeed, constitutive cleavage of @APP (Esch et al., 1990; Sisodia et al., 1990) gives rise to a large soluble form (-100 kDa) identical to protease nexin II (PN-II) (Oltersdorf et al., 1989; Van Nostrand et al., 1989) , leaving an -10 kDa fragment retained within the membrane (Selkoe et al., 1988) . In addition, other proposed functions for pAPP based on in vitro studies include an autocrine or growthpromoting function (Saitoh et al., 1989) , participation in cell adhesion as an extracellular matrix protein (Schubert et al., 1989a) , inhibition of coagulation factor XIa (Smith et al., 1990) , and as a cell surface receptor (Kang et al., 1987) .
There is great interest in the role of the APP fragment of pAPP in the pathogenesis of Alzheimer's disease, particularly in view of recent observations that amorphous, largely nonfilamentous deposits of APP may precede the development of the other cytopathological lesions of Alzheimer's disease and trisomy 2 1 by years or decades (see, e.g., Tagliavini et al., 1988; Yamaguchi et al., 1988; Giaccone et al., 1989; Joachim et al., 1989b,c; Motte and Williams, 1989; Rumble et al., 1989 ; for review, see Selkoe, 1989) . The apparent early deposition of A@P focuses increased attention on the unresolved question of which cells produce the pAPP molecules that are alternatively processed to release the A@P peptide. The juxtaposition of PAPP-rich neuronal cell bodies and neurites to cortical A@P plaques has fueled interest in the hypothesis that neurons are the source of p-amyloid (Masters vessel wall-or blood-derived cells could produce the amyloiet al., 1985a; Koo et al., 1990) . The occurrence of many microvascular deposits of APP, including in meningeal arteries outside the brain parenchyma, has supported the notion that nofluorescence, cells were grown-for at least 2-3 d before fixation.
Pure populations of astrocytes were obtained using a modification of the method of McCarthy and de Vellis (1980) . Source cultures were shaken overnight at 250 rpm at 37°C. Medium containing loose cells was removed, and the remaining cell layer was trypsinized and replated onto either nlastic dishes or nolvlvsine-coated coverslins. For immudogenic peptides (Joachim et al., 1989a; Selkoe, 1989) . Besides these potential sources, it is known that reactive astrocytes and activated microglia are intimately associated with A@P deposits in most mature ("classical") and some immature ("diffuse") plaques (see, e.g., Schechter et al., 1981; Probst et al., 1987; Itagaki et al., 1989; Rozemuller et al., 1989; Wisniewski et al., 1989) . The detection of @APP proteins and mRNAs in cerebral astrocytes both in situ (Card et al., 1988; Siman et al., 1989; Golde et al., 1990 ) and in vitro (Berkenbosch et al., 1990; Ohyagi et al., 1990) has suggested that plaque-associated astrocytes could serve as a source of APP in Alzheimer's disease. Berkenbosch and colleagues reported that type I astrocytes in primary mixed glial cultures of 2-3-d-old rats produced only PAPP,,,; no KPIcontaining forms of @APP were detected by Northern and Westem blotting or immunocytochemistry. This result is surprising, since all other non-neuronal and neuronal cells reported to date have been found to express some PAPP,,,. The identification and characterization of @APP in microglial cells have not been reported.
In this study, we report the substantial expression of all three major forms of @APP (695, 751, and 770) in both astrocytes and microglia cultured from newborn rat cerebral cortex. Biosynthetic labeling and immunoprecipitation reveal that these BAPP isoforms are rapidly turned over, yet relatively small amounts of the constitutively cleaved, soluble amino-terminal fragment are secreted into the media. PCR-mediated amplification of the corresponding mRNAs shows that all three transcripts occur in rather equal amounts. Immunocytochemistry localizes full-length BAPP to membranous cytoplasmic organelles, particularly perinuclear vesicles, with very little insertion at the cell surface. In addition, we show that the relative production of soluble isoforms of /3APP is dependent on the cell type and isoform analyzed. Taken together, our data indicate that both astrocytes and microglia produce substantial amounts of all three @APP isoforms but process some of these molecules by a mechanism other than the constitutive proteolytic pathway identified in other cell types.
Materials and Methods
Preparation of primary cell cultures. Primary source cultures of rat glial cells were prepared as described by McCarthy and de Vellis (1980) , with minor modifications. Briefly, the cerebral cortices of I-2-d-old rats (Charles River Breeding Labs, Wilmington, MA) were dissected, and the meninges were removed. The tissue was trypsinized (0.25% for 20 min), mechanically dissociated by repeated passage through a Pasteur pipette, and directly plated into flasks containing Dulbecco's modified Eagle's medium (DMEM) (GIBCO Laboratories, Grand Island, NY) supplemented with 10% fetal calf serum (Sigma Chemical Co., St. Louis, MO). Cells were maintained in a humidified incubator at 37°C 5% CO, for 2-3 weeks. From these source cultures, microglial cells were isolated as previously described (Graeber et al., 1989) as modified from the methods of Frei et al. (1987) and Giulian and Baker (1986) . Cells growing on top of a confluent cell layer were removed by vigorous agitation and plated either into 6 cm plastic dishes or onto polylysine-coated glass coverslips. After 30 mitt, nonadherent cells were removed and fresh culture medium was added. For immunofluorescence, microglia were plated at a density of -5-10 x 10' cells/cm2. After l-2 d, cells were processed for further analysis as described below.
Hippocampal neurons were prepared from the brains of 17-18-d-old rat fetuses, as described by Banker and Cowan (1977) and Bartlett and Banker (1984) . Hippocampi were trypsinized (0.25%, 15 min at 37"(Z), washed with Ca-and Mg-free Hanks' balanced salt solution, and dissociated by passage through a Pasteur pipette. The cell suspension was plated at very high density into polylysine-coated 60 mm dishes (l-2 x lo6 cells/dish) with DMEM containing 10% horse serum. After 3 hr at 37°C the medium was removed, and the cultures were maintained in DMEM supplemented with the N2 mixture of Bottenstein and Sato (1979) for 3-4 d.
Antibodies against p-amyloid precursor protein. Antibody orR1285 was produced against a synthetic peptide corresponding to residues 527-540 of PAPP,,, (numbering of Rang et al., 1987) and is similar to antibody R36 raised by Ishii et al. (1989) to the same sequence. This polyclonal antiserum was prepared as previously described (Selkoe et al., 1988) . To recognize C-terminal epitopes, antibody cuC7 raised against a synthetic peptide of the last 20 amino acids of OAPP (Podlisny et al., 1990) was used. For affinity purification of (uR1285 and (uC7, the corresponding peptides were coupled to a mixture of Affigel-10 and Affigel-15 (Bio-Rad, Richmond, CA) according to the protocol of the manufacturer. The antibodies were bound overnight at 4°C. Proteins bound nonspecifically were removed by washing the column with 20 vol of 0.3 M Tris-buffered saline (TBS; 10 mM Tris, pH 7.6,0.3 M NaCl, 0.3% Triton X-100) after which the column was washed with 2 vol of PBS to remove residual T&on X-100. The affinity-purified antibodies were then eluted with 2.5 vol of 0.2 M glycine (pH 2.5) and immediately neutralized with Tris. The specificity of the affinity-purified antibodies was tested by immunoblotting (data not shown). Monoclonal antibody (mAb) 22Cll (Boehringer Mannheim, Indianapolis, IN) was used to label N-terminal epitopes of @APP specifically.
Gel electrophoresis and immunoblotting. Total cell extracts were prepared according to Weidemann et al. (1989) . These extracts were separated on 7.5% and 10% polyacrylamide gels (Laemmli, 1970 ) and transferred to nitrocellulose filters using standard conditions. For immunoblotting, membranes were blocked for 1 hr in 50% horse serum in TBS ( 10 mM Tris, pH 7.6, 140 mM NaCl) followed by a 1 hr incubation with the antiserum. Filters were washed 3 x 20 min in 0.5 M TBS (10 mM Tris, pH 7.6, 0.5 M NaCl, 0.5% Triton X-100). The alkaline phosphatase-coupled secondary antibody (Promega Corp., Madison, WI) was used in a 1:7500 dilution in TBS, 5% horse serum. After a 1 hr incubation, filters were washed as described above. Color development was done according to standard conditions. Metabolic labeling and immunoprecipitation. For metabolic labeling, BAPP-transfected human 293 kidney cells (Selkoe et al., 1988; Oltersdorf et al., 1989) and astrocytes were grown to about 90% confluence in 6 cm dishes. Microglial cells were plated to about 90% confluence. After removal of culture medium, 2 ml of methionine-free DMEM were added, and the cells were labeled for 12 hr with 150 PCi L-YS-methionine (New England Nuclear, Boston, MA). Preparation of cell extracts was done as described above. For analysis of soluble forms of PAPP, the medium was centrifuged at 10,000 x g in a Sorvall HB4 rotor for 1 hr. The supematant was carefully removed and used for immunoprecipitation. Immunoprecipitations from cell extracts or media were carried out according to Weidemann et al. (1989) with the following modifications: immunoprecipitates were washed three times for 20 min each at 4°C in 0.5 M STENI50 mM Tris, pH 7.5, 0.5 M NaCl, 2 mM EDTA, 0.2% Nonidet P-40 (NP-4O)l. SDS-STEN (50 mM Tris. DH 7.5. 150 mM NaCl, 2 mM EDTA: O.l"h SDS), and STEN (50 mM T&s, pH'7.5, 150 mM NaCl, 2 mM EDTA, 0.2% NP-40). The buffers were supplemented with 2 mM phenylmethylsulfonyl fluoride and 50 &ml leupeptin. Immunoprecipitated proteins were separated on 10% polyacrylamide gels and fixed in Coomassie blue. After incubation of the gel in Enhance (New England Nuclear), labeled proteins were visualized by autoradiography. For immunoprecipitations, we used the number of dishes described in Results. One 6 cm dish contained about 2-3 x 1 O6 kidney 293 cells, about 1.5 x lo6 astrocytes, or about 1 x lo6 microglial cells. For pulse-chase experiments, astrocytes were pulse labeled with 150 PC1 of L-YS-methionine for 20 min followed by the indicated chase periods using media containing an excess of unlabeled methionine. For each time point, 3 x 1 O6 astrocytes were labeled. Immunoprecipitations were performed as described above using antibody otC7.
Isolation of total RNA and PCR amplification of mRNA. Total RNA was isolated from tissue culture cells using the guanidinium-thiocyanate procedure (Maniatis et al., 1989) . For PCR-mediated amplification of human OAPP mRNAs, we used the following oligonucleotide primers: KPI-R, which corresponds to the reverse sequence of OAPP (Kang et al., 1987) between base pairs (bp) 921 and 901 (GGC-GGATCCAGGTGTCTTCGAGATACTTGT), and KPI-F between bp 834 and 853 (GGCGAATTCACCACAGAGTCTGTGGAAG) (Podlisny et al., 199 1). The corresponding rat-specific primers were KPI-R rat (GGCGGATCCGGGGG TCTCCAGGTACTTGT) and KPI-F rat (GGCGAATTCTACCACTGAGTCTGTGGAGG) according to the sequence published by Shivers et al. (1988) . The KPI-F primers contained an EcoRI restriction site at the 5' end, and the KPI-R primers contained a BamHI restriction site (underlined in the sequences).
For first-strand cDNA synthesis, we used 1 ng of the KPI-R primer in a mix containing 1 pg of total RNA, 0.5 ~1 of RNasin (Promega), 19.5 U of reverse transcriptase, and 1.25 mM dNTP mix in 1 x reverse transcriptase buffer. The reaction was incubated at 37°C for 1 hr. Five microliter aliquots of these reactions were used in PCR reactions (Saiki et al., 1988) .
Zmmunocytochemistry. Cells plated onto glass coverslips were fixed in -20°C methanol for 10 min, followed by brief fixation in acetone (50%. 2 min: 100%. 3 min: 50%. 2 mitt). Nonspecific binding of primary'antibody was blocked by incubation in PBS containing 2% goat serum for 60 min at 37°C. The cells were then incubated with primary antibody either at 37°C for 3 hr, or at 4°C overnight. After five 5 min washes in PBS, the appropriate secondary antibody [tetramethylrhodamine isothiocyanate (TRITC)-conjugated goat anti-rabbit IgG, fluores&n isothiocyanate (FITC)-conjugated goat anti-mouse IgG, Boehringer Mannheim] was added for 60 min at room temperature. Coverslips were then washed as before. To confirm identification of the micro&al cells, a monoclonal antibody against rat macrophage surface antigen CR3 (0X42; Accurate Chemical and Scientific, Westbury, NY) was used. Astrocyte identity was confirmed with a polyclonal antiserum raised against glial fibrillary acidic protein (GFAP) (the kind gift of Dr. D. Dahl. West Roxburv V. A. Medical Center. Boston. MA).
To label specifically epitopes present on the cell surface, we used the double-labeling method described by Bakke and Dobberstein (1990) , with modifications.
Cells plated on polylysine-coated coverslips were incubated with mAb 22Cll for 1 hr on ice and washed five times for 3 min each in PBS containing 2% horse serum (PBS-HS). All subsequent washes were carried out in like manner. The cells were then labeled with FITC-conjugated goat anti-mouse IgG for 45 min on ice. After washing with PBS-HS, the cells were fixed with 4% paraformaldehyde, 0.12 M sucrose for 20 min at room temperature, followed by 0.1 M glycine for 5 min to block remaining paraformaldehyde activity. The cells were then permeabilized with 0.1% Triton X-100 for 5 min at room temperature and washed with PBS-HS. Incubations with a second pAPP antibody, &7, and its corresponding secondary antibody were done at room temperature for 60 min and 45 min, respectively. The converse experiment was also performed. As a control for specific antibody labeling of antigens either on the cell surface or within the cell, mAb OX42 was applied to cultured microglia either before or after fixation and Triton permeabilization.
Results
Detection of BAPP in cultured astrocytes and microglia In order to characterize the expression of pAPP in astrocytes and microglial cells, we established primary tissue cultures from the cerebral cortex of newborn rats. From these cultures, we isolated essentially pure populations of microglia and astrocytes. Ameboid microglia were identified based on their staining with a monoclonal antibody (0X42) against the rat macrophage surface antigen CR3 (C3bi complement receptor) (Robinson et al., 1986) . Furthermore, these cells were peroxidase negative, distinguishing them from peripheral macrophages or monocytes (Giulian and Baker, 1986) . Astrocyte cultures were confirmed to be GFAP positive by immunostaining. Both CR3(+) microglial cultures and GFAP(+) astrocyte cultures in these purified cell populations were greater than 95% pure, based on immunocytochemistry (data not shown).
Identical amounts of total cell homogenates of both cell types were prepared and immunoblotted with a high-titer antiserum (cuC7) produced to a synthetic peptide of amino acids 676-695 of pAPP (Podlisny et al., 1990) . As a control in this and all further experiments, we examined human embryonic kidney 293 cells stably transfected with cDNAs coding for PAPP,,, (Selkoe et al., 1988) or PAPP,,, (Oltersdorf et al., 1989) . As shown in Figure la , aC7 identifies full-length @APP in all cell types analyzed; the migration of these bands is consistent with previously published results on other cells and tissues (Selkoe et al., 1988; Weidemann et al., 1989) . Unexpectedly, a high amount of @APP expression was detected in astrocytes (compare lane 4 with lanes 2 and 3). Astrocytes contained amounts of immunoreactive pAPP comparable to the transfected 293 cells, whereas microglial cell extracts showed slightly lower amounts of pAPP (lane 5). For a more detailed analysis, the cell extracts were separated on a 7.5% gel (Fig. 1 b) . As judged by corn&ration with the BAPP of the two transfected cell lines, astrocytes and microglial cells contain all major @APP isoforms. Band 6 and band 4 ( 1 and 3) . Bands 2 and 3 are of unidentified origin but most likely represent posttranslationally modified or slightly degraded forms of PAPP. Although PAPP,,, is not directly resolved on immunoblots, its presence was confirmed by PCR analysis of mRNA derived from microglia and astrocytes (discussed below). In addition to full-length PAPP, we also detected the -10 kDa fragment (see below) that has previously been shown to remain in the cell membrane after the precursor is constitutively cleaved to produce soluble /?APP (Selkoe et al., 1988; Esch et al., 1990 ).
Mcroglia and astrocytes synthesize PAPP Since it is not clear whether microglial cells and astrocytes synthesize @APP or whether its immunochemical detection in those cells is due to uptake of PAPP, we metabolically labeled the primary tissue culture cells with r?S-methionine and immunoprecipitated pAPP with &7. Figure 2 shows that microglial cells and astrocytes synthesize pAPP from endogenous mRNA, since we obtained strong signals of labeled @APP after immunoprecipitation, comparable to those obtained from the PAPPtransfected kidney 293 cells. To prove the specificity of our immunoprecipitations, (uC7 was preabsorbed with its corresponding peptide; the reactivity with pAPP in each cell type was completely abolished (Fig. 2) . The high molecular weight bands seen above pAPP in the microglia and astrocyte lanes may represent coimmunoprecipitating proteins that are bound to PAPP. They are not detected in transfected kidney cells (Fig.  2) neurons, and PC12 cells (data not shown). Their presence in the immunoprecipitates is not due to a cross-reactivity with the antibody cK7, since we cannot detect the same bands by direct immunoblotting (compare Fig. 2 to Fig. la and b) .
By comigration with the transfected cells, we again observed that microglia and astrocytes synthesize at least PAPP,,, and PAPP,,, (Fig. 2) . They also contain a small amount of the -10 kDa fragment that is derived from proteolytic processing of pAPP (arrow in Fig. 2) . From these data, we conclude that pAPP a b detection in these cells is due to endogenous synthesis of OAPP and not to its uptake by endocytosis. To confirm that rat astrocytes and microglial cells indeed synthesize all three major forms of BAPP rather than only BAPP,,, (Berkenbosch et al., 1990) , we searched for mRNAs coding for the KPI-containing @APP forms. For this purpose, we used primers upstream and downstream of the human/rat KPI domain (see Materials and Methods) to amplify mRNAs coding for all three major pAPP isoforms. From the sequence published for rat pAPP (Shivers et al., 1988) , we expected to obtain amplified cDNAs of 273 and 330 bp from mRNA coding for @APP,,, and PAPP,,,, respectively, and a small cDNA of 105 bp for PAPI',,, . The results are shown in Figure 3 . As a control, we again used the transfected and untransfected kidney 293 cells. From microglial cells and astrocytes, we obtained three PCRamplified products of the expected length for ,f3APP,,,, PAPP,,,, and /3APP770. All three mRNAs are present in rather similar amounts. To confirm further that these cDNAs are derived from /3APP mRNAs, they were subcloned into Bluescript vectors and sequenced (data not shown). Sequence analysis revealed that all three cDNAs are identical with the corresponding regions of the three /3APP isoforms. These data clearly confirm that astrocytes and microglial cells synthesize all three major /?APP isoforms.
Detection of soluble @APP in microglia and astrocytes
In addition to full-length BAPP, aC7 immunoprecipitated the -10 kDa fragment shown in Figure 2 . Relative to levels in the transfected kidney 293 cells, both astrocytes and microglia produce much less 10 kDa peptide (Fig. 2) . Moreover, the two transfected lines contain different amounts of this fragment. Interestingly, we have consistently observed a higher production of the 10 kDa and other C-terminal-containing proteolytic fragments (M. B. Podlisny and D. J. Selkoe, unpublished observation) in the PAPP,,, transfectants compared to PAPP,,, transfectants (see Fig. 2 ). To quantify the observed differences in the amount of the 10 kDa fragment among the cells being studied, we analyzed the (uC7 immunoprecipitates by densitometry. For a better comparison, we also added immunoprecipitates from extracts of primary hippocampal neurons cultured from 18-dold rat embryos. For quantification, we compared the amount of all full-length BAPP bands, regardless of glycosylation state, with the amount of the 10 kDa band. This was necessary because the immature N'-glycosylated forms could not be resolved from the mature N'-and 0'-glycosylated forms while preserving the 10 kDa fragment within the same lane. As a result, the quantitation (Fig. 4) reflects a relative, rather than absolute, ratio of 
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the ! 0 kDa fragment to full-length BAPP. The comparison shows The differences in the relative amounts ofthe 10 kDa fragment clearly that the transfected cells contain much higher amounts in astrocytes and microglia versus the kidney cells could be due of the 10 kDa fragment than the other cell types analyzed. In to reduced production and secretion of soluble pAPP or to enaddition, PAPP,,, transfected cells show almost twice as much hanced turnover of the 10 kDa fragment in the glial cells. To of the 10 kDa fragment as PAPP,,, transfected cells. The other distinguish between these possibilities, we first examined the cell types contain rather small amounts of the 10 kDa fragment. production of soluble ,BAPP forms by immunoprecipitating solInterestingly, the amount of production of the 10 kDa fragment uble pAPP from the conditioned media of metabolically labeled is not solely dependent on the major @APP isoform being excells with antibody cuR1285, which is directed against residues pressed by the analyzed cell type. For example, the result with 527-540 of PAPP. Using the same amount of astrocytes and the transfected cells could indicate that PAPP,,, transfectants microglial cells as in the experiment described in Figure 2 , we produce higher amounts of the 10 kDa fragment because that were unable to immunoprecipitate soluble BAPP from tissue pAPP isoform lacks the protease inhibitor domain. On the other culture supematants, whereas we precipitated large amounts of hand, in neurons, which also express primarily PAPP,,, (data the soluble form from the transfected 293 cell media (Fig. 5 , not shown), we detected only very small amounts of the 10 kDa lanes 2,3). When three times as many glial cells were used, very fragment.
small amounts of soluble BAPP, derived from both PAPP,,, and PA-',,, 9 could be immunoprecipitated (Fig. 5, lanes 4, 5) . Despite a slightly higher production of the -10 kDa fragment in microglia (see Fig. 4 ), we obtained a weaker signal for the soluble forms in conditioned media from microglia than from astrocytes. This may be due to the lower overall synthesis of @APP in microglial cells (see Fig. 2 ). Our data suggest that astrocytes and microglia produce reduced amounts of the soluble BAPP forms, despite a high level of synthesis ofthe precursor molecule. Nevertheless, it is still conceivable that this is due only to slower processing through the constitutive secretory pathway. If @APP is indeed processed solely by the secretory pathway in glial cells, full-length forms should be turned over more slowly.
To rule out this possibility, pulse-chase experiments were performed on cultured astrocytes. Figure 6 shows that the estimated half-life of full-length @APP is about 30-45 min. The short half-life is consistent with data presented by Weidemann et al. (1989) and Oltersdorf et al. (1990) , who determined the half-life of BAPP in cells that produce high amounts of soluble PAPP. Furthermore, the 10 kDa fragment in the astrocytes is stable over a 4 hr chase period (Fig. 6 ). These data show that, while astrocytes do not produce significant amounts of the soluble and 10 kDa forms, they turn over full-length pAPP at rates comparable to other cells, thereby suggesting the existence of alternative processing pathways.
In addition to the two soluble ,@APP derivatives, we also obtained a 31 kDa fragment in immunoprecipitates from the conditioned media of microglial cells using antibody (~R1285 (Fig. 5, arrow) . This fragment, which is currently being further characterized, has not been detected in all other cell types so far analyzed. Immunocytochemical detection of pAPP in microglial cells and astrocytes We examined the subcellular localization of /3APP in cultured cells by indirect immunofluorescence. Using affinity-purified antibody oC7 (to DAPP residues 676-695) on primary rat microglia, we observed a punctate, perinuclear staining pattern suggestive of Golgi membranes (Fig. 7a-c) . Furthermore, some cytoplasmic vesicles stained intensely for PAPP. Antibody aR1285 gave an identical pattern (data not shown). A monoclonal antibody (0X42) against the rat macrophage surface antigen CR3 recognized epitopes with a similar intracellular distribution. In contrast to j3APP antibodies, however, OX42 showed definite immunoreaction at the cell surface (Fig. 7a'-c' ). In view of the previous characterization of pAPP as a transmembrane glycoprotein (Rang et al., 1987) , its limited presence on cell surface membranes is somewhat unexpected. Astrocyte staining similarly revealed a granular distribution of /3APP centered around the nucleus and again showed nearly no cell surface staining (Fig. 8a) . This vesicular pattern differs strikingly from the cytoskeletal pattern of an antibody against GFAP (Fig. 8b ) that was used to confirm the identity of astrocyte cultures. The pattern of immunoreactivity with antibodies against ,f3APP in these cell types is similar to that found in the transfected 293 cells (Selkoe et al., 1988) . To confirm the apparent lack of cell surface staining, we performed double labeling of cultured microglia in which cell surface proteins are labeled on living, unfixed cells (Bakke and -10 kD Figure 6 . A pulse-chase experiment using primary astrocytes. Cells were pulse labeled for 20 min and chased in medium containing excess amounts of unlabeled @APP for the indicated time periods. Immunoprecipitations were performed using antibody &7. While the 10 kDa fragment (arrow) is present in very small amounts, it is still stable after a 4 hr chase period. The half-life of full-length BAPP is about 30-45 min. Since astrocytes express all three major forms of BAPP, it is not possible to analyze the process of glycosylation in detail. The autoradiogram was exposed for 6 d. Dobberstein, 1990) . Using the monoclonal antibody 22C11, which recognizes the extreme N-terminus of @APP (following the signal peptide), to label living cells, we observed a very low amount of cell surface staining, whereas c&7 produced strong intracellular staining within the same cells after permeabilization with 0.1% Triton X-100 (compare Fig. 9 , a and b, with Fig.   9 , a' and b'). If 22C 11 was applied after Triton permeabilization, it similarly demonstrated the presence of abundant intracellular pAPP (data not shown). In contrast, the control antibody 0X42, raised against a cell surface protein, revealed strong cell surface labeling prior to cell permeabilization; after Triton treatment, intracellular vesicular staining was also seen (Fig. 9c,d ). Similar results were obtained with astrocytes (data not shown). While a lack of cell surface staining would not be unexpected in cells that secrete large amounts of soluble PAPP, it is surprising that full-length forms in glial cells that are not cleaved also do not arrive at the cell surface. These data, together with the reduced production of the 10 kDa fragment (Fig. 4) and the soluble derivatives of pAPP (Fig. 5) indicate that @APP mediates its biological function in these cells only to a minor extent as a surface protein.
Discussion
Among mammalian tissues examined to date, brain has been found to have the highest level of expression of PAPP. Although neuronal transcription of /3APP has been extensively studied by in situ hybridization of brain sections and biochemical analysis of cultured neuronal-like cells (see, e.g., Bahmanyar et al., 1987; Goedert, 1987; Cohenet al., 1988; Higginsetal., 1988; Schubert et al., 1989b , Johnson et al., 1990 , there is limited information about astrocytic pAPP expression, and the presence of pAPP in microglia has not been reported. Both astrocytes and microglia are prominent constituents of the APP-rich neuritic plaques that occur abundantly in Alzheimer's disease and ttisomy 21 and,
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Figure 7. Immunocytochemical analysis of BAPP expression in microglial cells from primary cultures of rat cortex. Cells were fixed with methanol/acetone (see Materials and Methods) and then double labeled with a polyclonal antibody against @APP (&T) and a monoclonal antibody (0X42) against the macrophaae surface ant&en CR3. The ~olv-clonai antibody was identified with TRITC-conjugated goat anti-rabbit IgG, and the monoclonal antibody, with FITC-conjugated goat antimouse IgG. u-c, Three examples of microglial cells demonstrating expression of@APP using affinity-purified antibody (uC7. Note the granular vesicular staining concentrated in the perinuclear cytoplasm. a'+', Same cells as in u-c, stained with mAb 0X42, thus confirming their identity as microglial cells. Note the prominent cell surface localization in addition to the punctate intracellular staining seen with 0X42. Scale bar, 10 pm.
to a lesser extent, during normal brain aging. Here, we characterize the expression of PAPP in primary cultures of cortical microglia and astrocytes. We show that both cell types synthesize substantial amounts of BAPP. However, in comparison to published studies of cDNA-transfected cells (Weidemann et al., 1989; Oltersdorf et al., 1990) , microglia and astrocytes show markedly reduced processing of full-length pAPP into soluble, secreted forms. As shown by pulse labeling of astrocytes, this is not merely due to a slower cleavage rate of the precursor molecule, since full-length pAPP is still rapidly turned over (with a half-life of about 30-45 min) in astrocytes. In these cells, pAPP is localized in intracellular vesicles and displays very little insertion at the cell surface. Our findings lead to the hypothesis that PAPP, at least in CNS glial cells, may have an intracellular function rather than serving principally as a precursor for soluble pAPP derivatives that act extracellularly.
The small amounts of soluble, carboxyl-truncated ,f3APP we detected in the conditioned media of astrocytes and microglia were reflected in the low levels of the constitutive -10 kDa carboxyl-terminal fragment found in cell lysates. As shown in Figure 4 , densitometric quantitation of the ratio of 10 kDa to full-length pAPP forms provides a simple and rapid method for comparing the extent of pAPP processing through the constitutive proteolytic pathway in primary cultured cells or permanent cell lines. Among the three major CNS cell types we have analyzed, all show much less constitutive processing of pAPP into secreted forms than do the transfected cells that have been used to characterize the metabolic fate of BAPP heretofore (Weidemann et al., 1989; Esch et al., 1990; Oltersdorfet al., 1990 ). Interestingly, the lowest level of 10 kDa production we observed occurred in neurons (Fig. 4) . If our results in primary cultures of cortical cells reflect the situation in brain, then neurons, astrocytes, and microglia may process only a minority of fulllength pAPP molecules through the constitutive secretory pathway, leaving most molecules inserted into membranes. Our immunocytochemical results demonstrate very little insertion of the precursor at the cell surface and abundant /3APP in membranous organelles in the cytoplasm. Taken together, these findings lead to the hypothesis that a significant portion of BAPP in glial cells may remain in the endoplasmic reticulum, Golgi complex, or other internal vesicular components and thus may serve primarily an intracellular function.
In addition to the implications of this hypothesis for models ofPAPP as a cell surface receptor (Kang et al., 1987; Weidemann et al., 1989) or principally as a precursor for PN-II secretion (Oltersdorf et al., 1989; Van Nostrand et al., 1989) it has implications for current ideas about the alteration of normal PAPP processing in Alzheimer's disease. The finding by Esch et al. (1990) that constitutive secretion of PN-II involves a proteolytic cleavage at residue 16 within the A/?P region (residue 6 12 of PAPP,,,) has led to the concept that the currently unidentified enzyme responsible for this clip (referred to as APP secretase) normally prevents generation of /3-amyloid and thus may be reduced in activity or otherwise inefficient in some cells in Alzheimer's disease. It could be further speculated that pharmacologically increasing the activity of APP secretase might enhance the constitutive cleavage of@APP and decrease the genesis of APP. However, the results reported here suggest that many pAPP molecules in neurons and glia may not be destined for processing by this pathway, and therefore the identification and subsequent modulation of APP secretase may not turn out to be an advantageous therapeutic target in Alzheimer's disease. Instead, many @APP molecules may function physiologically as full-length, membrane-bound polypeptides and then be catabolized through a normal pathway that involves generation of fragments that contain intact ABP and perhaps limited production of APP itself For example, our detection of a soluble 31 kDa protein with an antibody to ,f3APP residues 527-540 (and preliminarily with aC7) in the media of microglia raises the possibility that this is a catabolic fragment of the precursor protein that contains the A/3P region and is potentially amyloidogenic. The proteases responsible for the sequential degradative cleavages of PAPP, particularly those clipping at the Nand C-termini of ApP, remain potentially attractive targets for therapeutic intervention.
Another implication of our findings is that the extent to which full-length pAPP is constitutively processed to release PN-II varies considerably among different cells. For example, it is known that platelets stimulated with calcium ionophores or thrombin secrete large amounts of this C-truncated form (Bush et al., 1990; Cole et al., 1990; Smith et al., 1990; Van Nostrand et al., 1990) , which can then function as a soluble protease inhibitor. In addition, while platelets contain only small amounts of full-length PAPP, they contain large amounts of both PN-II and the 10 kDa fragment (M. Schlossmacher and D. J. Selkoe, unpublished observations) . This is consistent with our prediction that the ratio of the 10 kDa C-terminal fragment to fulllength pAPP forms is a useful monitor for measuring the degree of cleavage into PN-II. Our findings suggest that processing of @APP into soluble PN-II may be a function of both the cell type and the predominant isoforms of @APP being transcribed. In the kidney 293 cell line, PAPP,,,-transfected cells produce almost twice as much of the 10 kDa fragment as PAPP,,,-transfected sister cells grown simultaneously under identical conditions (Figs. 2, 4) . Since the only difference between these two populations of cells is the presence of the Kunitz protease inhibitor domain in the latter, one may assume that this domain is capable of inhibiting proteolysis of the precursor molecule by decreasing the activity of the APP secretase. On the other hand, such a mechanism cannot be responsible for the very low production of the 10 kDa fragment that we observed in primary cultures of fetal neurons, since neurons at this age have been shown to express much more PAPP,,, than PAPP,5, . We hypothesize that both cell type-specific and isoform-specific differences in the relative usage of various pAPP processing pathways are likely to exist.
The cells that synthesize those @APP molecules that give rise to microvascular and senile plaque amyloid deposits in aged and Alzheimer's disease brain tissue are currently unknown. Several laboratories have demonstrated a very close relationship among microglial cells, astrocytes, and mature amyloid-bearing senile plaques (see, e.g., Haga et al., 1989; Itagaki et al., 1989; Wisniewski et al., 1989; Cras et al., 1990) . Microglia are frequently found in the centers of such plaques, within the amyloid deposit, whereas astrocytes are often concentrated around the periphery of a plaque and appear to extend some processes toward the plaque center (Itagaki et al., 1989) . Both astrocytes (Siman et al., 1989) and microglia (Wisniewski et al., 1989) have been postulated as the cells of origin of senile plaque amyloid. Indeed, Wisniewski et al. (1989) have examined senile plaques by electron microscopy and described vesicles derived from the Golgi apparatus apparently fusing with so-called amyloid-filled channels in the cytoplasm of microglial cells. This appearance led these investigators to propose that microglial cells do not take up the amyloid fibrils by phagocytosis, as one would expect for a macrophage-like cell, but rather are the cells that make /3-amyloid.
Our data show that microglial cells synthesize all three major isoforms of @APP and have a low rate of proteolytic cleavage of the precursors within the APP region. However, this does not necessarily implicate these cells as the source of plaque amyloid. Most amorphous or diffuse ABP plaques, which are believed to represent very early deposits that may serve as a precursor of mature senile plaques, are not specifically associated with microglial cells, as judged by HLA-DR labeling (Itagaki et al., 1989) . For example, in Alzheimer's disease cerebellum, where numerous diffuse qBP plaques occur with very little or no surrounding neuritic alteration, we were unable to demonstrate any spatial association with HLA-DR-positive microglia, whereas this marker readily identified reactive microglia in most mature plaques of the cerebral cortex from the same brain (Joachim et al., 1989~) . Similarly, GFAP-positive reactive astrocytes are usually not detectable in diffuse plaques. Since such diffuse APP deposits seem to precede by many years the appearance of mature plaques, neuritic dystrophy, neurofibrillary tangles, and other cortical lesions in Down's syndrome (Giaccone et al., 1989) and, by implication, in Alzheimer's disease, it is unlikely that reactive microglia or astrocytes are the source of the initial deposition of A@P in these disorders. Nevertheless, our findings that these cell types synthesize large amounts of PAPP, at least in vitro, suggest that there could be multiple cellular sources for the ApP deposited within mature amyloid plaques. cLm.
